Executive and Business Leadership

Mason Kauffman, President, Chief Executive Officer, Board Chairman – Kauffman received his BS from the University of Michigan and MBA from the University of Memphis. He was part of FedEx’s pioneering teams from 1978-1994 before leaving to found, grow, and sell his own businesses. Those companies, Express Logistics and Accuship, earned Inc. Magazine’s 500 Fastest Growing Company status. Kauffman was recognized as Entrepreneur of the Year by Ernst & Young, as an industry “mover and shaker” by Bloomberg Businessweek, and as a “leader in the pack” by LEADERS Magazine.

Chris Przybyszewski, Executive Vice President, Board Secretary – Przybyszewski earned his BA from the University of Pennsylvania and his MA from the University of Memphis. He has spent his career working with physicians and scientists in the neuroscience, medical device, and vaccines fields, where he has helped them translate basic technologies into implementable programs and products. By providing strategic planning and implementation expertise, Przybyszewski has helped build multi-national public-private programs funded by government, foundation, and industry partners.

Dave Williams, Board Member – Williams holds a degree in Accounting and Management from Scranton University and retired in 2008 as Chairman & CEO of Sanofi Pasteur, the vaccines business of Sanofi-Aventis Group. Williams’ thirty years with the company was marked by his rise from Finance Manager, to General Manager of the US Business unit, to being named the company’s U.S. President of the company. He was later named Global President & COO in 1998. Williams’ leadership moved the company from a niche vaccine business to the global leader in vaccine development, production, and sales, with 2007 revenues of more than US $6 billion. Sanofi Pasteur is the largest vaccine business in the world and but also provides the broadest range of vaccines available from a single company.

Under Williams’ guidance, more than one billion doses of Sanofi Pasteur’s lifesaving vaccines were administered to more than 500 million people around the world each year, representing more than 25% of the global vaccine market. The company grew to almost 13,000 employees, licensed more than 30 new vaccines and launched hundreds of business development programs under Williams’ leadership.

Michael Shmerling, Board Member –Shmerling received his Bachelor of Accountancy degree from the University of Oklahoma and is a veteran entrepreneur who has established and grown profitable companies in a wide spectrum of industries, including finance, consumer products, and corrections, among others. Shmerling began his career as a CPA with Ernst & Young and has since founded five businesses, four of which were acquired by publicly traded companies.

At present, Shmerling serves as Chairman of Clearbrook Holdings Corp., a management and investment holding company. In addition, Shmerling serves on the board of several companies including Choice Food Group, Inc., Maynard Select, LLC, and Health Connect America, Inc. In 2007, he was awarded the American Institute of CPA’s Public Service Award.

Gov. Tommy Thompson, Board Member – Gov. Thompson served as Wisconsin’s governor for fourteen years, focusing on the revitalization of the state’s economy. Through these efforts, Gov. Thompson gained national attention for his leadership on welfare reform, expanding access to health care for low-income people, and education. In 2001, Gov. Thompson accepted the nomination for U.S. Secretary of Health and Human Services.

As the nation’s leading advocate for the health and welfare of all Americans, Gov. Thompson led the department which employed more than 60,000 personnel and had a fiscal year 2001 budget of $429 billion. Gov. Thompson now serves on several strategic healthcare-related boards and served as the Chairman of Deloitte’s Global Healthcare Practice focusing on Health Care Management and Transformation.

Steve Good, Senior PMP and T&O Advisor – Good received his BA in Economics from the University of Memphis and has since become one of the pest-management industry’s leading marketing and sales executives with a focus on bringing new products to market, expanding national markets, and M&A activities. In his executive leadership roles at Terminix, Good provided sales leadership, business strategy development, brand positioning, direct marketing, media advertising, public relations, promotions, and product placement across multiple verticals. He oversaw the successful integration of these business development strategies to help propel Terminix to their industry leadership position while overseeing a $60M annual marketing budget, managing a global sales force of over 1,500, and generating over $500,000,000 in annualized sales.

Science and Regulatory Affairs Leadership

Steve Zatechka, PhD, MBA, Chief Science Officer – Zatechka earned his PhD from the University of Nebraska Medical Center and his MBA from the University of Memphis. He completed his postdoctoral fellowship with the Howard Hughes Medical Institute at St. Jude Children’s Research Hospital. Zatechka is experienced in the development and utilization of gene targeting technologies for animal models and the development of applied biotechnology-based protocols. Zatechka is the inventor of US BIOLOGIC’s patented production platform technology.

Dr. Ed Robb, DVM, Senior Product Development & Regulatory Advisor – Dr. Robb earned his BS and DVM from Cornell University and subsequently served as a veterinarian in New York. Following his interest in research and large-scale solutions to health problems, Dr. Robb attended the University of Pennsylvania, earning his MS in Epidemiology.

From Penn, Dr. Robb has influenced the research and commercialization of animal health products for over 30 years and has become one of the few veterinarians of his generation who actively practiced research, He quickly became a strategic innovation leader in several of the industry’s largest companies, including Pharmacia, Pfizer, Boehringer-Ingelheim Vetmedica, Ceva, and Parnell Pharmaceuticals.

Robb’s career has been highlighted by bringing several products through their earliest R&D phases, through clinical trials, and then to market.

Dr. Luciana Meirelles Richer, DVM, MSc, Principal Scientist & Laboratory Director – Richer earned her DVM from State University of Sao Paulo, Brazil and MSc in Veterinary Sciences from Federal University of Rio Grande do Sul, Brazil. She has worked on oral vaccine projects against Lyme disease and other infectious diseases with Dr. Maria Gomes-Solecki, as well as several ground-breaking methodologies for tick-borne disease diagnostic tools. Richer brings vast animal model experience for vaccine delivery and diagnostics, as well as great expertise in microbiology and immunology. She is the lead author on several pivotal publications, including Reservoir Targeted Vaccine Against Borrelia burgdorferi: A New Strategy to Prevent Lyme Disease Transmission.

Colonel (ret) Tom Monath, MD, Board Director – Dr. Monath received his AB degree from Harvard College and his MD from Harvard Medical School and currently serves as Managing Partner and Chief Scientific Officer of Crozet Biopharma. He is an internationally recognized virologist and vaccinologist with over 50 years’ experience in research on viral and bacterial diseases, 25 of which have been in the vaccines industry. His expertise spans discovery research and all functional areas of product development. He has worked in leadership positions in US government agencies and in the biotechnology sector. He had primary responsibility for bringing multiple innovative vaccines into clinical development, including Ebola Zaire, cell-based smallpox, dengue, Japanese encephalitis, West Nile, cytomegalovirus, influenza, live and inactivated yellow fever, Helicobacter pylori, Clostridium difficile, four of which are now licensed and commercialized.

Before forming Crozet, Dr. Monath was CSO and COO of BioProtection Systems, the infectious disease subsidiary of NewLink Genetics, where he led the development of the recombinant vesicular stomatitis vectored Ebola vaccine funded by BARDA and DTRA in partnership with Merck, and he initiated and led development efforts on a new Zika vaccine.

Prior, he was Chief Medical Officer of Hookipa Biotech, Juvaris and Xcellerex and CSO and an Executive Director of Acambis before its acquisition by Sanofi Pasteur. In that position he developed a novel platform for vaccine development (ChimeriVax™) and brought three human and one veterinary vaccine through regulatory approval, including ACAM2000® smallpox vaccine under $500m development and procurement contracts from HHS.

Along with his duties at US BIOLOGIC, Dr. Monath currently serves on the boards of Juvaris Inc. and Sentinext Plc and on the Scientific Advisory Boards of RapidMicro Biosystems, GeoVax and SutroVax. Between 2006-1012, Dr. Monath was a Partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm where oversaw investments in the vaccine space. Before joining industry, Dr. Monath served in the uniformed services of US Public Health Service and the US Army for 24 years, retiring as a Colonel. During that time Dr. Monath served as Director, Division of Vector-Borne Viral Diseases at the Centers for Disease Control and Prevention and Chief, Virology Division at the US Army Medical Research Institute of Infectious Diseases.

He has received many prestigious awards, including the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), the Walter Reed Medal (2002) and the James H. Steele Gold-Headed Cane Award (2015). He has served on numerous government and international committees on infectious diseases, biosecurity, WHO expert committees and the National Vaccines Advisory Committee (USA), and is Past-President of the American Society of Tropical Medicine and Hygiene and an elected Fellow of the Society. He has been a leader in and founding member of the One Health Initiative and is an expert in arthropod-borne viruses. He has published over 425 scientific papers and six books on virology and vaccine development and has thirty-five patents.

Dr. Stephen Wikel, PhD, Senior Science Advisor – Dr. Wikel received a Ph.D. from the University of Saskatchewan and went on to serve as a staff fellow at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, as well as Professor and Acting Chair, Department of Immunology, School of Medicine, University of Connecticut. He subsequently served as Professor of Pathology, University of Texas Medical Branch and Senior Scientist at the Center for Tropical Diseases and Center for Biodefense and Emerging Infectious Diseases, Galveston National Laboratory.

In 2011, Dr. Wikel was appointed Senior Associate Dean, Professor and Chairman, Department of Medical Sciences, and St. Vincent’s Medical Center Endowed Chair, School of Medicine, Quinnipiac University, as one of four deans to establish a new school.

Dr. Wikel has led worldwide research collaborations in tick physiology and genetic discovery research, as well as host immunological responses and vector countermeasures to host defenses at the arthropod vector-host-pathogen interface; the role of those interactions on blood feeding and pathogen transmission; and, development of novel immune-based anti-vector and pathogen transmission blocking control strategies.

Dr. Wikel has ninety-one peer reviewed publications and sixteen invited review and book chapters on these topics. He has been a featured speaker for seventy-five national or international symposia. Dr. Wikel received extramural research support for his program from the National Institutes of Health, U.S. Army Medical Research and Materiel Command, Centers for Disease Control and Prevention, U.S. Department of Agriculture and industry. He has extensive service experience as a member of advisory panels, research study sections, editorial boards and academic institution administration.

Louise Henderson - Resized for WebsiteDr. Louise Henderson, PhD, USDA/CVB Consultant – Dr. Henderson received her BS, MS, and Ph.D., Molecular, Cellular, & Developmental Biology from the Iowa State University and later served as a manager in PEL at the USDA APHIS CVB as a manager in PEL in 2008 and has since been a consultant in veterinary biologics. She served as Chief of Biotechnology, Immunology, and Diagnostics. She was responsible for overseeing policy, laboratory testing, and review and approval of licensing submissions for all biotechnology, immunology, and diagnostic products. She also has expertise in regulatory jurisdiction issues for those products that may be either a veterinary biologic regulated by the USDA or a veterinary drug regulated by the FDA.

Maria Gomes-Solecki, DVM, Inventor – Dr. Gomes-Solecki earned her DVM from the University of Lisbon, completed a Fellowship at the National Institute of Technology, Lisbon, Portugal, and her post-doctorate work at Stony Brook University. She is now an Associate Professor of Microbiology and Immunology, University of Tennessee Health Science Center, serves as president of Immuno Technologies, and is the inventor of US BIOLOGIC’s first oral vaccination technology. In 2014, Dr. Gomes-Solecki was recognized as the “Innovator of the Year” by MBQ Magazine.

Public Programs Leadership

Sanford Kaufman, Senior Political Advisor – Kaufman earned his MS degree in Biology from St. John’s University and his MPA from New York University. He has over twenty years of experience leading the State Government Affairs function at Sanofi Pasteur, the vaccine subsidiary of Sanofi Aventis. Over that time, he led lobbying and public policy initiatives in over forty states and interacted with major policy organizations in the public health arena.

Colonel (ret) Steven Swann, MD, FACS, Senior Medical Advisor – Col. Swann holds his BS from Tennessee Technological University, his MD from the Uniformed Services University of the Health Sciences, and his MNSS from the National War College.

 Following thirty-four years of service as an Army Physician, Col. Swann retired as Command Surgeon, US Special Operations Command. In this role, Col. Swann served as the Senior Physician for all of the Department of Defense’s Special Operations Forces worldwide. Previously, Col. Swann served as Commander of the 3,000 man 30th Medical Brigade, US Army Europe, and deployed the Brigade to Iraq during 2005-2006.

Col. Swann has also commanded the Joint Medical Augmentation Unit, JSOC, Fort Bragg, NC; Bayne-Jones Army Community Hospital, Fort Polk; the 31st CSH, Fort Bliss, TX, and the 168th Medical Battalion, Taegu, South Korea.

Major General (ret) William K. Suter, Political Adviser – After receiving his BA degree from Trinity University and his JD degree from Tulane University School of Law, Gen. Suter served in numerous positions of responsibility around the world, including Appellate Judge, Deputy Staff Judge Advocate of the U.S. Army Vietnam, Staff Judge Advocate of the 101st Airborne Division, Commandant of the JAG School, and the Assistant Judge Advocate General of the Army. Gen. Suter has recently retired as the 19th Clerk of the Supreme Court of the U.S. where he served for twenty-two years. Gen. Suter also served as Army Judge Advocate before retiring as a Major General.

To contact US BIOLOGIC, please email us at info@usbiologic.com.